Ge Long Hui·2026-02-24 08:45Core Viewpoint - The company has received approval from the National Medical Products Administration of China for an expanded age range for its meningococcal polysaccharide conjugate vaccine, MCV4, from children aged 3 months to 3 years to children aged 3 months to 6 years [1] Group 1 - The approval allows the company's product, MCV4 (marketed as Manhaixin®), to be administered to a broader age group, enhancing its market potential [1] - Manhaixin® is the first quadrivalent meningococcal conjugate vaccine in China, addressing the gap in high-end vaccines in the country and reducing the disparity with developed nations [1] - The vaccine provides a superior solution for the prevention of meningococcal disease in children aged 6 years and below, showcasing strong market performance and increasing market share [1]